VERTEX PHARMACEUTICALS INC / MA 4

Director Alan M. Garber received an award of approximately 31.56 deferred stock units of Vertex Pharmaceuticals Inc. (VRTX), valued at about $475, as part of routine board compensation.

On July 15, 2026, Vertex Pharmaceuticals Inc. director Alan M. Garber received an award of deferred stock units that will convert into shares of common stock upon the earliest of his termination from the board, a change in control of the company, or his disability or death. The Form 4 indicates an acquisition of approximately 31.56 deferred stock units valued at about $475.28 in total, implying a reference value of roughly $15.07 per unit, with each unit representing one share of common stock. Following this grant, Garber beneficially owns about 65.458 shares (or equivalent units) on a direct basis. This appears to be a routine board compensation grant rather than an open-market trade.

Filing Facts

CIK

875320

Ticker

VRTX

Form

4

Source Type

fda

Accession

0000875320-26-000247

Alert Tier

4